Your session is about to expire
← Back to Search
Paclitaxel for Gastrointestinal Disorders
Study Summary
This trial is studying a combination of paclitaxel, mitomycin, and cisplatin given as hyperthermic intraperitoneal chemotherapy (HIPEC) to find the best dose to control gastric or gastroesophageal cancer.
- Gastrointestinal Disorders
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
To what medical conditions is Paclitaxel typically recommended as a treatment?
"Paclitaxel is a widely-used medication administered to patients weighing 40 kg or more. Its potential applications extend beyond this, as it has proven useful in managing helicobacter pylori infection, synovitis and metastatic bladder cancer."
Is acceptance for individual participation in this trial still ongoing?
"The evidence on clinicaltrials.gov suggests that this research initiative is no longer actively recruiting participants, having been initially posted in October of 2017 and last updated in September 2021. However, there are presently 5140 other studies searching for patients across the United States."
Has the FDA given its stamp of approval to Paclitaxel?
"Paclitaxel's safety is estimated to be a 1 due to limited evidence regarding its efficacy and safety, as this trial falls under the Phase 1 designation."
How many individuals are actively involved in this clinical experiment?
"Unfortunately, this clinical research is no longer recruiting patients. As per the information on clinicaltrials.gov, it was initially posted on October 27th 2017 and last updated September 7th 2022. However, there are presently 3297 other trials with fever as an inclusion criteria and 1923 studies examining Paclitaxel that are still admitting participants."
Share this study with friends
Copy Link
Messenger